NO330217B1 - Alfa-tymosinpeptid for beskyttelse av celler mot stralingsskade. - Google Patents

Alfa-tymosinpeptid for beskyttelse av celler mot stralingsskade. Download PDF

Info

Publication number: NO330217B1
Authority: NO; Norway
Prior art keywords: alpha; thymosin; peptide; composition; thymosin peptide
Prior art date: 2002-11-25

Application number

NO20052943A

Other languages

English (en)

Norwegian (no)

Other versions

NO20052943D0 (no

NO20052943L (no

Inventor

Alfred R Rudolph

Cynthia W Tuthill

Original Assignee

Sciclone Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-25

Filing date

2005-06-16

Publication date

2011-03-07

2005-06-16 Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc

2005-06-16 Publication of NO20052943D0 publication Critical patent/NO20052943D0/no

2005-08-09 Publication of NO20052943L publication Critical patent/NO20052943L/no

2011-03-07 Publication of NO330217B1 publication Critical patent/NO330217B1/no

Links

230000005855 radiation Effects 0.000 title claims abstract description 26
230000006378 damage Effects 0.000 title claims abstract description 21
108090000765 processed proteins & peptides Proteins 0.000 title claims description 31
239000000203 mixture Substances 0.000 claims description 34
108010078233 Thymalfasin Proteins 0.000 claims description 25
102400000800 Thymosin alpha-1 Human genes 0.000 claims description 24
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical group CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 24
229960004231 thymalfasin Drugs 0.000 claims description 24
229920000642 polymer Polymers 0.000 claims description 19
230000037396 body weight Effects 0.000 claims description 10
238000001802 infusion Methods 0.000 claims description 10
206010073306 Exposure to radiation Diseases 0.000 claims description 9
229920001223 polyethylene glycol Polymers 0.000 claims description 9
238000002347 injection Methods 0.000 claims description 7
239000007924 injection Substances 0.000 claims description 7
229920000233 poly(alkylene oxides) Polymers 0.000 claims description 6
229920001400 block copolymer Polymers 0.000 claims description 4
229920001577 copolymer Polymers 0.000 claims description 3
229920001519 homopolymer Polymers 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
230000001681 protective effect Effects 0.000 claims description 2
230000004223 radioprotective effect Effects 0.000 claims description 2
229920005862 polyol Polymers 0.000 claims 2
150000003077 polyols Chemical class 0.000 claims 2
229920003169 water-soluble polymer Polymers 0.000 claims 2
229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
-1 polyoxyethylene Polymers 0.000 claims 1
108010046075 Thymosin Proteins 0.000 abstract description 38
238000011282 treatment Methods 0.000 description 21
210000004027 cell Anatomy 0.000 description 20
102000007501 Thymosin Human genes 0.000 description 10
241001465754 Metazoa Species 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
230000004083 survival effect Effects 0.000 description 7
230000003021 clonogenic effect Effects 0.000 description 6
239000002202 Polyethylene glycol Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
238000000034 method Methods 0.000 description 5
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 4
230000000694 effects Effects 0.000 description 4
150000001413 amino acids Chemical group 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
210000000130 stem cell Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
239000011324 bead Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
229920002307 Dextran Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
201000010927 Mucositis Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
244000309466 calf Species 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000005025 clonogenic survival Effects 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000007547 defect Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
239000000834 fixative Substances 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000018925 gastrointestinal mucositis Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000004088 simulation Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
108700016958 thymosin fraction 5 Proteins 0.000 description 1
239000000724 thymus hormone Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Zoology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Dermatology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

NO20052943A 2002-11-25 2005-06-16 Alfa-tymosinpeptid for beskyttelse av celler mot stralingsskade. NO330217B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US42874602P	2002-11-25	2002-11-25
PCT/US2003/037469 WO2004048971A1 (en)	2002-11-25	2003-11-25	Methods of protecting against radiation damage using alpha thymosin

Publications (3)

Publication Number	Publication Date
NO20052943D0 NO20052943D0 (no)	2005-06-16
NO20052943L NO20052943L (no)	2005-08-09
NO330217B1 true NO330217B1 (no)	2011-03-07

Family

ID=32393452

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20052943A NO330217B1 (no)	2002-11-25	2005-06-16	Alfa-tymosinpeptid for beskyttelse av celler mot stralingsskade.

Country Status (16)

Country	Link
US (1)	US7897567B2 (de)
EP (1)	EP1570269B1 (de)
JP (1)	JP2006507349A (de)
KR (1)	KR20050086819A (de)
CN (1)	CN100501400C (de)
AT (1)	ATE511852T1 (de)
AU (1)	AU2003295838B2 (de)
BR (2)	BR0316646A (de)
CA (1)	CA2506893A1 (de)
EA (1)	EA008059B1 (de)
MX (1)	MXPA05005538A (de)
NO (1)	NO330217B1 (de)
NZ (1)	NZ540847A (de)
PL (1)	PL377376A1 (de)
UA (1)	UA81932C2 (de)
WO (1)	WO2004048971A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100311656A1 (en) *	2003-04-23	2010-12-09	Sciclone Pharmaceuticals, Inc.	Treatment or prevention of respiratory viral infections with alpha thymosin peptides
US20060246057A1 (en) *	2003-07-18	2006-11-02	Regenerx Biopharmaceuticals, Inc	Treatment or prevention of damage due to radiation exposure
JP5307559B2 (ja) *	2006-03-07	2013-10-02	バイオテンプトビー．ブイ．	放射線障害の制御の為にペプチドを使用する方法
US20140213506A1 (en) *	2011-02-09	2014-07-31	Cynthia W. TUTHILL	Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
US20130296223A1 (en) *	2012-03-30	2013-11-07	Sciclone Pharmaceuticals, Inc.	Use of thymosin alpha for the treatment of sepsis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1195980A (en) *	1966-08-24	1970-06-24	Univ Yeshiva	Hormone-Like Preparations Derived from Thymus Gland and Methods of Producing the Same.
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4079127A (en) *	1976-10-28	1978-03-14	Board Of Regents Of The University Of Texas	Thymosin alpha 1
US4116951A (en)	1977-04-22	1978-09-26	Hoffmann-La Roche Inc.	[Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en)	1978-01-23	1979-04-10	Hoffmann-La Roche Inc.	Synthesis of thymosin α1
DE2919592A1 (de) *	1979-05-15	1981-01-15	Max Planck Gesellschaft	Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5122614A (en)	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
CN1094310A (zh)	1992-12-15	1994-11-02	托马斯·C·梅里根	人体免疫缺陷性病毒感染用组合式化学疗法
TW252045B (de) *	1993-10-07	1995-07-21	Allan L Goldstein
ES2174915T3 (es)	1993-11-10	2002-11-16	Enzon Inc	Productos de conjugacion mejorados de un interferon con un polimero.
US5908621A (en)	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
US6197751B1 (en) *	1997-11-10	2001-03-06	The United States Of America As Represented By The Department Of Health And Human Services	Thymosin α1 promotes tissue repair, angiogenesis and cell migration
US6309633B1 (en) *	1999-06-19	2001-10-30	Nobex Corporation	Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
CN1303713A (zh)	2000-01-07	2001-07-18	广州暨南大学医药生物技术研究开发中心	预防和治疗辐射损伤的保健组合物
US6462017B1 (en) *	2000-05-01	2002-10-08	Sciclone Pharmaceuticals, Inc.	Method of reducing side effects of chemotherapy in cancer patients
ATE537845T1 (de)	2000-10-31	2012-01-15	Pr Pharmaceuticals Inc	Verfahren zur herstellung von formulierungen zur verbesserten abgabe von bioaktiven molekülen
UA78726C2 (en)	2001-11-01	2007-04-25	Sciclone Pharmaceuticals Inc	Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
UA80957C2 (en) *	2001-11-01	2007-11-26	Sciclone Pharmaceuticals Inc	Method of administering a thymosin alpha 1 peptide

2003
- 2003-11-25 EP EP03787049A patent/EP1570269B1/de not_active Expired - Lifetime
- 2003-11-25 WO PCT/US2003/037469 patent/WO2004048971A1/en active Application Filing
- 2003-11-25 BR BR0316646-5A patent/BR0316646A/pt not_active Application Discontinuation
- 2003-11-25 KR KR1020057009427A patent/KR20050086819A/ko not_active Application Discontinuation
- 2003-11-25 JP JP2004555637A patent/JP2006507349A/ja active Pending
- 2003-11-25 US US10/535,835 patent/US7897567B2/en not_active Expired - Fee Related
- 2003-11-25 AU AU2003295838A patent/AU2003295838B2/en not_active Ceased
- 2003-11-25 EA EA200500773A patent/EA008059B1/ru not_active IP Right Cessation
- 2003-11-25 CA CA002506893A patent/CA2506893A1/en not_active Abandoned
- 2003-11-25 CN CNB200380104130XA patent/CN100501400C/zh not_active Expired - Fee Related
- 2003-11-25 AT AT03787049T patent/ATE511852T1/de not_active IP Right Cessation
- 2003-11-25 PL PL377376A patent/PL377376A1/pl not_active Application Discontinuation
- 2003-11-25 NZ NZ540847A patent/NZ540847A/en not_active IP Right Cessation
- 2003-11-25 UA UAA200506230A patent/UA81932C2/uk unknown
- 2003-11-25 BR BRPI0316646A patent/BRPI0316646A8/pt unknown
- 2003-11-25 MX MXPA05005538A patent/MXPA05005538A/es unknown
2005
- 2005-06-16 NO NO20052943A patent/NO330217B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1717587A (zh)	2006-01-04
UA81932C2 (uk)	2008-02-25
ATE511852T1 (de)	2011-06-15
BRPI0316646A8 (pt)	2018-04-24
JP2006507349A (ja)	2006-03-02
CA2506893A1 (en)	2004-06-10
EP1570269A1 (de)	2005-09-07
EA008059B1 (ru)	2007-02-27
AU2003295838A1 (en)	2004-06-18
KR20050086819A (ko)	2005-08-30
NZ540847A (en)	2006-07-28
EA200500773A1 (ru)	2005-12-29
NO20052943D0 (no)	2005-06-16
EP1570269B1 (de)	2011-06-08
NO20052943L (no)	2005-08-09
PL377376A1 (pl)	2006-02-06
AU2003295838B2 (en)	2008-05-22
EP1570269A4 (de)	2008-09-10
US7897567B2 (en)	2011-03-01
MXPA05005538A (es)	2005-08-16
WO2004048971A1 (en)	2004-06-10
BR0316646A (pt)	2005-10-11
US20060166877A1 (en)	2006-07-27
CN100501400C (zh)	2009-06-17

Publication	Publication Date	Title
CN102176900B (zh)	2017-09-26	药物组合物和相关的给药方法
EP1592384B1 (de)	2012-10-31	Cop 1 zur behandlung entzündlicher darmerkrankungen
CN100536910C (zh)	2009-09-09	胸腺素α1肽/聚合物结合物
NO330217B1 (no)	2011-03-07	Alfa-tymosinpeptid for beskyttelse av celler mot stralingsskade.
JP5031827B2 (ja)	2012-09-26	予防或いは肝損傷を治療するペプチッド
DE69633919T2 (de)	2005-12-01	Mehrzweckvakzine gegen umhüllte viren
CN101559217A (zh)	2009-10-21	7p肽的口服给药途径及其在预防或治疗肾炎中的应用
Fayaz et al.	1981	Booster effect of human diploid cell antirabies vaccine in previously treated persons
EA009945B1 (ru)	2008-04-28	Способ лечения или профилактики респираторной коронавирусной инфекции с использованием пептидов альфа-тимозина
WO2016160429A1 (en)	2016-10-06	Glycoconjugate vaccine for leishmaniasis
UA82097C2 (uk)	2008-03-11	Спосіб лікування або профілактики респіраторної коронавірусної інфекції пептидом альфа-тимозину
US20150011471A1 (en)	2015-01-08	Regeneration of islet beta cells by hsp60 derived peptides
US20030060413A1 (en)	2003-03-27	Derivatives of pseudo-peptides, their preparation and their biological uses
Root-Bernstein	2009	A measles-derived peptide treats and vaccinates against adjuvant arthritis

Legal Events

Date	Code	Title	Description
2012-06-25	MM1K	Lapsed by not paying the annual fees